Table 1.
Patient groups according to reasons for IVIg treatment.
| n (%) | |
|---|---|
| Group 1: Patients requiring antiinflammatory treatment but complicated with secondary infection and/or sepsis | 17 (36.9) |
| Secondary infection | 12 (26.1) |
| Sepsis | 5 (10.9) |
| Group 2: Patients with Covid-19 related complications | 18 (39.1) |
| Progressive disease refractory to other antiinflammatory agents | 12 (26.1) |
| Myocarditis/adult multisystem inflammatory syndrome | 3 (6.5) |
| Hemophagocytic lymphohystiocytosis like syndrome |
3 (6.5) |
| Group 3: Patients with other complications non-specific to Covid-19 |
11 (23.9) |
| Hematologic | 5 (10.9) |
| Acute myelogenous leukemia | 2 (4.3) |
| Hypogammaglobulinemia with chronic lymphocytic leukemia |
2 (4.3) |
| Trombocytopenia | 1 (2.2) |
| Neurologic | 4 (8.6) |
| Postcovid myopathy | 2 (4.3) |
| Postcovid Guillian-Barre syndrome | 1 (2.2) |
| Myastenia gravis | 1 (2.2) |
| Vasculitic | 2 (4.3) |
| Kawasaki | 1 (2.2) |
| Granulomatosis with polyangiitis | 1 (2.2) |
COVID-19: coronavirus disease 2019, n: number.